Patents Assigned to Neuren Pharmaceuticals Ltd.
-
Patent number: 9708366Abstract: This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder—Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.Type: GrantFiled: January 27, 2012Date of Patent: July 18, 2017Assignee: NEUREN PHARMACEUTICALS LTD.Inventors: Larry Glass, Michael John Bickerdike, Michael Frederick Snape
-
Patent number: 9119851Abstract: Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions.Type: GrantFiled: June 25, 2014Date of Patent: September 1, 2015Assignee: NEUREN PHARMACEUTICALS, LTD.Inventors: Michael John Bickerdike, Jian Guan
-
Patent number: 8637567Abstract: This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function.Type: GrantFiled: October 13, 2010Date of Patent: January 28, 2014Assignee: Neuren Pharmaceuticals Ltd.Inventors: Peter David Gluckman, Jian Guan, Mary-Anne Woodnorth, Margaret Anne Brimble
-
Patent number: 7887839Abstract: Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.Type: GrantFiled: September 15, 2008Date of Patent: February 15, 2011Assignee: Neuren Pharmaceuticals Ltd.Inventors: Jingyuan Wen, Gregory Brian Thomas, Mike John Bickerdike
-
Patent number: 7776876Abstract: Embodiments of this invention provide methods for thereapeutic use of cyclic G-2-Allyl Proline to treat disorders of dopaminergic neurons, including Parkinson's disease. Cyclic G-2Allyl P is neuroprotective and has utility as a therapeutic agent for treatment of diseases and other conditions characterised by degeneration and/or death of dopaminergic neurons and the adverse symptoms of such degeneration and/or death. Such symptoms include loss of cognition and motor function. Compounds are also useful for manufacture of medicaments including tablets, capsules and injectable solutions that are useful for treatment of such conditions.Type: GrantFiled: April 7, 2006Date of Patent: August 17, 2010Assignee: Neuren Pharmaceuticals, Ltd.Inventors: Margaret Anne Brimble, Jian Guan
-
Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
Patent number: 7767786Abstract: The invention discloses a family of neuronal migration-inducing, proliferation-promoting and neurite outgrowth promoting factors, termed NRP compounds, and provides compositions and methods for the use of NRP compounds in the treatment of brain injury and neurodegenerative disease. NRP compounds induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient.Type: GrantFiled: August 22, 2002Date of Patent: August 3, 2010Assignee: Neuren Pharmaceuticals Ltd.Inventors: Frank Sieg, Paul Hughes -
Publication number: 20090304700Abstract: The present invention relates to conformation specific antibodies to TFF and compositions thereof. The present invention also relates to methods of regulation of cellular proliferation, survival and/or oncogenicity, particularly methods for the treatment of cancers, tumors and proliferative disorders.Type: ApplicationFiled: June 5, 2009Publication date: December 10, 2009Applicant: NEUREN PHARMACEUTICALS, LTD.Inventor: PETER E. LOBIE
-
Patent number: 7304029Abstract: The invention relates to neuroprotection and to medicaments for use therein. Neuroprotection is induced by activation of neural growth hormone receptors, primarily using medicaments comprising growth hormone, growth hormone analogs or ligands which are functionally equivalent. Such medicaments may also include one or more secondary neuroprotective agents.Type: GrantFiled: September 3, 1999Date of Patent: December 4, 2007Assignee: Neuren Pharmaceuticals Ltd.Inventors: Arjan Scheepens, Christopher E. Williams, Peter David Gluckman, Ross Graham Clark
-
Patent number: 7282342Abstract: GPE antibodies recognize GPE with high specificity. When used in a radioimmunoassay, they reliably measure the concentration of GPE. They may be used to extend the half-life of GPE both in vivo and in vitro, and in methods of purifying the GPE receptor. Two methods of rpHPLC accurately revolve GPE on the basis of its hydrophobicity.Type: GrantFiled: October 31, 2006Date of Patent: October 16, 2007Assignee: Neuren Pharmaceuticals Ltd.Inventors: David Charles Batchelor, Gregory Brian Thomas, Bernhard Hermann Heinrich Breier
-
Publication number: 20070128660Abstract: GPE antibodies recognize GPE with high specificity. When used in a radioimmunoassay, they reliably measure the concentration of GPE. They may be used to extend the half-life of GPE both in vivo and in vitro, and in methods of purifying the GPE receptor. Two methods of rpHPLC accurately revolve GPE on the basis of its hydrophobicity.Type: ApplicationFiled: October 31, 2006Publication date: June 7, 2007Applicant: Neuren Pharmaceuticals Ltd.Inventors: David Batchelor, Gregory Thomas, Bernhard Heinrich Breier
-
Patent number: 7192931Abstract: This invention relates to methods for the treatment or prevention of central nervous system (CNS) cell damage and functional damage in mammals due to demyelinating disease including multiple sclerosis. More specifically, the invention comprises a method of treating a demyelinating disease of the CNS in a mammal, the method comprising co-administering to the mammal, either sequentially or simultaneously, GPE or analogues or peptidomimetics or a prodrug thereof, or a pharmaceutically acceptable salt thereof, and an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionate)/kainate antagonist, or a pharmaceutically acceptable salt thereof, and an anti-inflammatory agent.Type: GrantFiled: October 11, 2001Date of Patent: March 20, 2007Assignee: Neuren Pharmaceuticals Ltd.Inventors: Geoffrey Wayne Krissansen, Jagat Rakesh Kanwar
-
Publication number: 20060217295Abstract: Embodiments of this invention provide novel peptidomimetics that contain a macrocycle. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.Type: ApplicationFiled: March 16, 2004Publication date: September 28, 2006Applicant: NEUREN PHARMACEUTICALS LTD.Inventors: Paul Harris, Margaret Brimble
-
Patent number: 7112570Abstract: The invention relates to GPE analogs, particularly GPE analogs capable of inducing an equivalent physiological effect to GPE within a patient. Such GPE analogs include peptides where the Gly of Gly-Pro-Glu is replaced by any of Ala, Ser, Thr, or Pro; where the Pro of Gly-Pro-Glu is replaced by any of Ala, Ser, Thr, or Gly; and where the Glu of Gly-Pro-Glu is replaced by any of Asn, Asp, or Gln. The GPE analogs of the invention have application in any method of therapy or prophylaxis in which GPE has application. These applications include the treatment of acute brain injury and neurodegenerative disease, including but not limited to injury or disease in the CNS. The GPE analogs will normally be administered as part of a pharmaceutical composition or preparation.Type: GrantFiled: August 24, 2001Date of Patent: September 26, 2006Assignee: Neuren Pharmaceuticals, Ltd.Inventors: Peter Gluckman, Tajrena Alexi
-
Patent number: 7041314Abstract: This invention relates to analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic and anti-necrotic, to methods of making them, to pharmaceutical compositions containing them, and to their use.Type: GrantFiled: May 24, 2002Date of Patent: May 9, 2006Assignee: Neuren Pharmaceuticals Ltd.Inventors: Norman A. Abood, Margaret Anne Brimble
-
Publication number: 20060035279Abstract: Anti-GPE antibodies are provided that can be used to detect the presence of GPE in a sample. GPE antibodies can be raised against conjugated GPE to produce antibodies that are specific for a GPE that has been derivatized using a similar coupling chemistry as was used for making the GPE conjugate. To detect GPE in a sample, the sample is exposed to a derivatizing agent to produce a derivatized GPE that is recognized by the anti-GPE antibody. Using similar strategies, antibodies can be raised against other weakly immunogenic molecules (WIMs) that can be the basis for assays and kits for assaying for WIMs.Type: ApplicationFiled: October 22, 2004Publication date: February 16, 2006Applicant: Neuren Pharmaceuticals Ltd.Inventors: David Batchelor, Gregory Thomas, Bernhard Breier
-
Patent number: 6933282Abstract: Embodiments of this invention include methods for increasing the amount of the enzyme tyrosine hydroxylase (TH) in the central nervous system (CNS) of mammals in need of an increase in TH. Methods include the use of the tripeptide, gly-pro-glu (GPE) to increase TH in the CNS. GPE can increase the amount of TH and/or decrease the loss of TH in conditions characterized by a loss of dopamine, such as Parkinson's disease and CNS injury. GPE may act to increase the expression of TH or by inhibiting a decrease in TH expression within the CNS or by inhibiting the loss of TH-containing neurons within the CNS. By increasing the amounts of TH in the CNS, GPE can increase the amount of the neurotransmitter, dopamine, in areas of the CNS responsible for adverse symptoms of neural injury or disease.Type: GrantFiled: June 26, 2003Date of Patent: August 23, 2005Assignee: Neuren Pharmaceuticals Ltd.Inventors: Peter D. Gluckman, Jian Guan, Tajrena Alexi
-
Publication number: 20050131212Abstract: The invention discloses a family of peptides termed NRP compounds or NRPs that can promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation and/or neuronal survival, and provides compositions and methods for the use of NRPs in the treatment of brain injury and neurodegenerative disease. NRP compounds can induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as exposure to toxins, stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient. NRP compounds can be formulated into pharmaceutically acceptable dose forms for therapeutic use.Type: ApplicationFiled: October 29, 2004Publication date: June 16, 2005Applicant: Neuren Pharmaceuticals Ltd.Inventors: Frank Sieg, Paul Hughes, Thorsten Gorba